| Study | Arm Dose mg/Day (N) | Duration (Weeks) | Population Trauma Type | Baseline PTSD Severitya | Mean Age (Y) | % Female | % Non-white | Risk of Bias |
|---|---|---|---|---|---|---|---|---|
| Brady et al., 200066 | Sertraline 25 to 200 mg (94) Placebo (93) | 12 | Male and female Mixed | 75.1 to 76.6 | 40 | 73 | 16 | Medium |
| Brady et al., 200567 | Sertraline 150 mg (49) Placebo (45) | 12 | Male and female Mixed, alcohol dependence | 57.6 to 60.1 | 37 | 46 | NR | Medium |
| Connor et al., 1999170 Meltzer-Brody et al., 2000171 | Fluoxetine 10 to 60 mg (27) Placebo (27) | 12 | Male and female Mixed | DTS 73.7 to 79.4 | 37 | 91 | 7 | Medium |
| Davidson et al., 200669 | Total 538b Venlafaxine 37.5 to 375 mg (179) Sertraline 25 to 200mg (173) Placebo (179) | 12 | Male and female Mixed | ~82 | NR | NR | NR | Medium |
| Davidson et al.,200168 | Sertraline 25 to 200 mg (100) Placebo (108) | 12 | Male and female Mixed | 73.5 to 73.9 | 37 | 78 | 17 | Medium |
| Friedman et al., 2007 70 | Sertraline 25 to 200 mg (86) Placebo (83) | 12 | Male and female Mixed (71% combat) | 72.1 to 73.8 | 46 | 20 | 71 | Medium |
| Li et al., 2017172 | Sertraline 135 mg (36) Placebo (36) | 12 | Male and female Mixed | IES-R 63.9 to 64.8 | 46 | 12 | 100 | Low |
| Marshall et al., 200164 | Paroxetine 20 mg (188) Paroxetine 40 mg (187) Placebo (188) | 12 | Male and female Mixed | 74.3 to 75.3 | 42 | NR (~2:1 F:M) | <10% | Medium |
| Martenyi et al., 200261; Martenyi et al., 2006173 | Fluoxetine 20 to 80 mg (226) Placebo (75) | 12 | Male and female Combat and victim/witness of war | 80.5 to 81.3 | 38 | 19 | 9 | Medium |
| Martenyi et al., 200762 | Fluoxetine 20 mg (163) Fluoxetine 40 mg (160) Placebo (88) | 12 | Male and female Mixed | 75 to 79 | 41 | 72 | 23 | Medium |
| Panahi et al., 201171 | Sertraline 50 to 200 mg (35) Placebo (35) | 10 | Male Combat | IES-R 65.1 to 65.4 | 46 | 0 | 100 | Low |
| Simon et al., 2008174 | Paroxetine 12.5 to 62.5 mg (11) Placebo (14) | 10 | Male and female Mixed (60% exposure to war; combat % NR), refractory to exposure | SPRINT 16.1 to 17 | 46 | 56 | 26 | Medium |
| Tucker et al., 200165 | Paroxetine 20 to 50 mg (163) Placebo (160) | 12 | Male and female Mixed | 73.2 to 74.3 | 41 | 66 | 28 | Medium |
| Tucker et al., 2003175 Tucker et al., 2004176 | Citalopram 20 to 50 mg (25) Sertraline 50 to 200 mg (23) Placebo (10) | 10 | Male and female Mixed | 83.9 to 94.2 | 39 | 74 | 14 | Medium |
| van der Kolk et al., 199463 | Fluoxetine 20 to 60 mg (33) Placebo (31) | 5 | Male and female Mixed (48% combat) | NR | 40 | 34 | NR | Medium |
| van der Kolk et al., 200747 | Fluoxetine (30) EMDR (29) Placebo (29) | 8c | Male and female Mixed | 71.2 | 36 | 83 | 33 | Medium |
| Zohar et al., 200272 | Sertraline 50 to 200 mg (23) Placebo (19) | 10 | Male and female Israeli military veterans | 91.2 to 93.3 | 40 | 12 | NR | Medium |
Data reported are mean CAPS or range of mean CAPS scores across groups unless otherwise specified.
The Ns for each are the number analyzed; the number randomized to each group was not reported (overall N was 538; 531 were included in the analysis).
Study was 8 weeks of treatment but also included a 6-month posttreatment followup.
CAPS = Clinician-Administered PTSD Scale; DTS = Davidson Trauma Scale; EMDR = eye movement desensitization and reprocessing; F = female; IES-R = Impact of Event Scale-Revised; mg = milligram; N = total number randomized/assigned to intervention and control groups; NR = not reported; PTSD = posttraumatic stress disorder; SPRINT = Short PTSD Rating Interview; y = year.
From: Results
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.